Theravance Biopharma Inc (TBPH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
901 Gateway Boulevard
South San Francisco, CA 94080
United States of America (the)
Phone
6508086000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
90
First IPO Date
May 16, 2014
| Name | Title | Pay | Year Born |
| Rick E. Winningham | Chief Executive Officer & Director | 1.47M | 1960 |
| Aziz Sawaf | Senior Vice President & Chief Financial Officer | 660,152 | 1982 |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial & Medical Affairs | 682,942 | 1965 |
| Brett A. Grimaud | Senior Vice President, General Counsel & Secretary | 690,870 | 1974 |
| Aine Miller | Senior Vice President of Development & Head of Ireland Office | 747,322 | 1977 |
| Stacy L. Pryce | Senior Vice President & Chief Strategy Officer | 0 | N/A |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer | 0 | N/A |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.